Document and Entity Information
Document and Entity Information | Aug. 14, 2023 |
Cover [Abstract] | |
Document Type | 8-K/A |
Document Period End Date | Aug. 14, 2023 |
Entity Registrant Name | MIND MEDICINE (MINDMED) INC. |
Entity Incorporation, State or Country Code | A1 |
Securities Act File Number | 001-40360 |
Entity Tax Identification Number | 98-1582438 |
Entity Address, Address Line One | One World Trade Center |
Entity Address, Address Line Two | Suite 8500 |
Entity Address, City or Town | New York |
Entity Address, State or Province | NY |
Entity Address, Postal Zip Code | 10007 |
City Area Code | 212 |
Local Phone Number | 220-6633 |
Title of 12(b) Security | Common Shares |
Trading Symbol | MNMD |
Security Exchange Name | NASDAQ |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Entity Emerging Growth Company | true |
Entity Ex Transition Period | false |
Entity Central Index Key | 0001813814 |
Amendment Flag | true |
Amendment Description | On August 14, 2023, Mind Medicine (MindMed) Inc. (the “Company”) filed a Current Report on Form 8-K (the “Original Filing”) to report that, on August 11, 2023, the Company and certain of its subsidiaries party thereto, as co-borrowers, entered into a Loan and Security Agreement with the lenders referred to therein (the “Lenders”), K2 HealthVentures LLC, as administrative agent and Canadian collateral agent for the Lenders, and Ankura Trust Company, LLC, as collateral trustee for the Lenders. This Form 8-K/A is being filed solely for the purpose of correcting a clerical error with respect to the Company’s jurisdiction of incorporation on the Cover Page of the Original Filing. The Original Filing is hereby amended to correctly identify the Company’s jurisdiction of incorporation as British Columbia, Canada. This amendment contains only the Cover Page to this Form 8‑K/A, this Explanatory Note and the Signature Page. Except for this correction, this amendment does not modify or update any disclosure contained in the Original Filing or its exhibits and should be read in conjunction with the Original Filing and its exhibits. |